abstract |
Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of α 1 -adrenergic agonists are physiologically active compounds including N.sup.δ -substituted ornithine or N.sup.ε -substituted lysine moieties or monoalkyl carbon-substituted N.sup.δ -substituted ornithine or N.sup.ε -substituted lysine moieties, having the formula ##STR1## wherein R is (CH 2 ) y CH 3 or H, R' is CH 2 or C(H)(CH 2 ) y CH 3 , and R" is CH 2 or C(H)(CH 2 ) y CH 3 , with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is alkyl having 1 to 5 carbon atoms, and physiologically acceptable acid addition salts thereof. |